PepGen: Stock Soars On DM1 Data, But Caution Warranted On Small Sample Sizes
Dyne Therapeutics to Participate in Upcoming Investor Conference
Is Dyne Therapeutics (DYN) Undervalued After Wider Losses And FDA Priority Review?
Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics Q3 EPS $(1.06) Misses $(0.92) Estimate
Oppenheimer Downgrades Dyne Therapeutics to Perform, Lowers Price Target to $15
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Why Dyne Therapeutics (DYN) Is Back In The Spotlight
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32
Dyne Therapeutics stock rises on positive DM1 trial results
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics Announces Additional One-Year Clinical Data From Phase 1/2 ACHIEVE Trial
Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target
Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative?
Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36
RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30
Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.